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Purpose: Gangrenous bowel, intraabdominal sepsis, and previous failed mesenteric bypass are indications for use of an
autogenous conduit for mesenteric arterial reconstruction. Saphenous vein (SV) is often used as the autogenous conduit
of choice, but it may be prone to graft stenosis or occlusion. Recent experience with superficial femoral vein (SFV)
suggests that it is an excellent alternative conduit for major arterial reconstruction. The purpose of this study was to
compare the outcomes of SV and SFV for mesenteric arterial bypass.
Methods: During a 7-year period, 26 patients underwent 43 mesenteric arterial bypass procedures with autogenous
conduit. SV was used for 23 bypasses (53%), and SFV was used for 20 bypasses (47%). Indications for revascularization
included chronic mesenteric ischemia (n  15; 58%), acute mesenteric ischemia (n  9; 35%), and mycotic aneurysm of
the paravisceral aorta (n 2; 7%). Three patients (11%) underwent revascularization with SV grafts and two patients (8%)
with SFV grafts after previous failed mesenteric bypass.
Results: The 30-day mortality rate was 15%. Three deaths occurred after SV bypass for acute mesenteric ischemia, and one
death occurred after a SFV bypass for a ruptured paravisceral mycotic aneurysm. Twenty-two surviving patients were
followed for a mean of 31 6 months. Three of 11 patients (27%) who survived after SV bypass had recurrent mesenteric
ischemia develop (acute, n 1; chronic, n 2) from graft thrombosis at a mean interval of 32 22 months after surgery.
No patient had recurrent symptoms develop after SFV bypass. One of the three patients with SV graft failure died of acute
mesenteric ischemia, and the other two patients underwent successful bypass with SFV. Symptomatic graft failure was
significantly more likely to occur in patients receiving SV grafts compared with SFV grafts (P < .05).
Conclusion: SFV yields acceptable clinical outcomes for mesenteric arterial bypass compared with SV. SFV is a viable
alternative to SV when autogenous conduit is indicated for mesenteric arterial reconstruction. (J Vasc Surg 2003;37:
362-6.)
Mesenteric arterial revascularization is indicated for the
treatment of symptomatic atherosclerotic occlusive disease
of the splanchnic arteries. Rarely, mesenteric arterial recon-
struction may be necessary as an adjunct to paravisceral
aortic reconstruction. Surgical options for revascularization
of mesenteric arteries include reimplantation, patch angio-
plasty, transaortic endarterectomy, and bypass.1-8 Among
these techniques, bypass grafting is most commonly used.
Recent reports have focused primarily on the optimal in-
flow site for bypass and the number of mesenteric arteries
that must be bypassed.1,7,9 To date, however, few reports
have focused on the optimal conduit for mesenteric arterial
bypass.10
Several series report acceptable long-term results with
prosthetic graft as the conduit for mesenteric bypass.7,9 An
autogenous graft may be preferable, however, in the pres-
ence of ischemic or gangrenous bowel or the presence of a
mycotic aneurysm. Prior prosthetic graft failure is an addi-
tional indication for an autogenous conduit, and some
surgeons simply prefer an autogenous conduit whenever
feasible. For most surgeons, saphenous vein (SV) is the
autogenous conduit of choice for mesenteric bypass. Our
extensive institutional experience with the superficial fem-
oral vein (SFV) as a conduit for in situ aortic reconstruction
after excision of infected prosthetic grafts11-13 led us to
investigate the use of SFV as an alternative autogenous
conduit for mesenteric arterial reconstruction. The purpose
of this study was to compare the outcomes of SV and SFV
for mesenteric arterial bypass.
PATIENTS AND METHODS
Study population. During a 7-year period (from
September 1993 to December 2001) during which all
operative cases were prospectively entered into a depart-
mental database, 41 patients underwent mesenteric artery
bypass procedures at the University of Texas Southwestern
Medical Center and its affiliated hospitals. Fifteen patients
underwent mesenteric bypass with a prosthetic conduit and
were excluded from this study. Twenty-six patients (63%)
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underwent 43 mesenteric bypasses with autogenous vein as
the conduit; they form the basis of this report. There were
16 female patients (62%) and 10 male patients (38%), with
a mean age of 63  3 years (range, 22 to 83 years).
Indications for surgery. Indications for surgery are
outlined in Table I. Twenty-four of the patients (92%)
underwent revascularization for mesenteric ischemia. Fif-
teen patients (58%) had symptoms of chronic mesenteric
ischemia, and nine patients (35%) needed revascularization
for acute mesenteric ischemia. Of the nine patients with
acute mesenteric ischemia, seven patients received SV by-
passes and two patients received SFV grafts. Two patients
(7%) needed mesenteric revascularization as an adjunct to
paravisceral aortic reconstruction for a mycotic aneurysm,
and both patients received SFV grafts. Five patients (19%)
had a previous failed mesenteric bypass. Two patients who
needed mesenteric revascularization after a prior failed mes-
enteric bypass received SV grafts, and three patients re-
ceived SFV grafts. Two of the patients undergoing second-
ary bypass with SFV had failed SV mesenteric arterial
bypasses, and both secondary SV bypasses followed failed
prosthetic mesenteric bypasses.
Conduit for bypass. Twenty-three bypasses (53%)
were performed with SV, and 20 bypasses (47%) used SFV
as the conduit. Patients who underwent elective operations
with SFV as the conduit were examined before surgery with
duplex ultrasonography for measurement of the diameter
of the SFV and identification of thrombosed, sclerotic, or
duplicated segments of SFV. SFVs that measured at least 6
mm in diameter were deemed adequate in size. The diam-
eter of SV grafts was not available for most patients, but our
standard protocol is to use SVs measuring at least 5 mm in
diameter for mesenteric arterial bypass. None of the oper-
ative reports described the SV as marginal or inadequate.
The technique for harvesting SFV has been described pre-
viously.14 The same criteria were used during emergency
operations to determine the suitability of SFV, on the basis
of direct inspection, to serve as a bypass conduit. Mesen-
teric arterial reconstructions routinely required shorter seg-
ments of vein than are required for aortofemoral bypass.
Only four cases required harvesting of the entire superficial
femoral-popliteal vein to the knee for thoracic aorta-mes-
enteric bypasses. The most proximal segment of SFV was
harvested, with care taken to transect the SFV precisely at
its junction with the profunda femoris vein. This technique
avoided the creation of a blind stump of SFV just below the
common femoral vein, which might predispose to throm-
bus formation and serve as a source of pulmonary embo-
lism.
Reconstructions. The operations performed are out-
lined in Table II. Most reconstructions (88%) were ante-
grade bypasses, and retrograde bypasses were distributed
nearly equally between SV and SFV bypass groups. Fifteen
patients (58%) received bypasses to both the superior mes-
enteric artery (SMA) and the celiac axis or its branches.
Eleven patients (42%) underwent bypass to the SMA alone.
Statistical analysis. Continuous data were expressed as
the mean  the standard error of the mean and were
compared between treatment groups with a Student t test.
Life-table patency rate for mesenteric bypass grafts was
calculated with the criteria recommended by the Ad Hoc
Committee on Reporting Standards of the Society for
Vascular Surgery/North American Chapter of the Interna-
tional Society for Cardiovascular Surgery.15 Log-rank test-
ing was used to compare clinical graft patency and objective
primary patency between SV and SFV grafts. For all statis-
tical analyses, the threshold for significance was .05. Statis-
tical analysis was performed with Statistical Package for the
Social Sciences software (version 7.5 for Windows, SPSS,
Inc, Chicago, Ill).
RESULTS
Short-term outcomes. Four patients (15%) died
within the 30-day perioperative period. Three of the peri-
operative deaths occurred in patients with acute mesenteric
ischemia, yielding a perioperative mortality rate of 33% for
acute mesenteric ischemia. One death occurred in a patient
with a ruptured mycotic paravisceral aortic aneurysm. All
who died of complications from acute mesenteric ischemia
received SV bypass grafts. The patient who died of a rup-
tured mycotic paravisceral aortic aneurysm received a SFV
bypass. In each case, a planned laparotomy to inspect the
viability of ischemic bowel confirmed patency of the bypass
graft, but the patients died of multiorgan failure (n 3) or
myocardial infarction (n  1). The three patients in whom
multiorgan failure developed after surgery had persistent
sepsis (n 2), renal failure (n 2), hepatic failure (n 1),
and myocardial infarction (n 1) before death. There were
no perioperative deaths in patients who underwent elective
revascularization for chronic mesenteric ischemia.
Postoperative complications occurred in 14 patients
(54%). Four of these patients had progression to multior-
gan failure and death, as noted previously. Among the
Table I. Indications for surgery
Presenting symptoms
No. of patients
SV SFV Total
Acute mesenteric ischemia 7 (27%) 2 (8%) 9 (35%)
Chronic mesenteric ischemia 7 (27%) 8 (30%) 15 (57%)
Paravisceral aortic reconstruction 2 (8%) 2 (8%)
Table II. Operations performed
Inflow artery
No. of patients
SV SFV Total
Antegrade bypasses 20 (46%) 18 (42%) 38 (88%)
Supraceliac aorta 18 (42%) 14 (32%) 32 (74%)
Thoracic aorta 2 (5%) 2 (5%) 4 (10%)
Celiac artery 1 (2%) 1 (2%)
Hepatic artery 1 (2%) 1 (2%)
Retrograde bypasses 3 (7%) 2 (5%) 5 (12%)
Common iliac artery 1 (2%) 1 (2%)
Prior aortofemoral bypass 2 (5%) 2 (5%) 4 (10%)
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patients who survived the perioperative period, the most
common complications were respiratory complications.
Two patients had pneumonia develop, and one patient
needed reintubation because of volume overload. One
patient had a perioperative cerebrovascular accident, and
one patient needed reoperation for an asymptomatic aortic
thrombus noted on routine postoperative arteriography.
Venous morbidity was minimal. One patient with a
SFV bypass graft reported transient postoperative swelling
of the donor lower extremity. No long-term swelling or
other venous morbidity was observed in any patient during
the extended follow-up period.
Late outcomes. Twenty-two patients who survived the
perioperative period were followed for a mean of 31  6
months (SV, 31 9 months; SFV, 27 6 months; P not
significant). Four patients died during the follow-up period
of causes unrelated to mesenteric ischemia at a mean of
24  10 months after surgery. All surviving patients had
initial relief of symptoms. Three of 11 patients (27%) who
survived after SV bypass had recurrent mesenteric ischemia
develop at a mean interval of 32 22 months after surgery.
Each of the three patients with recurrent mesenteric isch-
emia received antegrade SV graft bypasses to both the SMA
and the celiac axis, and all six bypasses were occluded on
arteriography. One of the three patients with SV graft
failure died of acute mesenteric ischemia, and the other two
patients had chronic mesenteric ischemia develop and un-
derwent successful mesenteric bypass with SFV. No patient
had recurrent symptoms develop after SFV bypass. Bypass
grafts in the two treatment groups were analyzed for the
incidence of symptomatic graft failure (Table III; Fig, A).
With the presence of recurrent symptoms of mesenteric
ischemia as an indicator of graft failure, there were six
known SV graft failures (26%) and no known SFV graft
failures. Each symptomatic SV graft failure was confirmed
with arteriography. With these criteria to define clinical
graft patency, life-table patency rates between SV and SFV
grafts were significantly different (P  .045 with log-rank
test; Table III; Fig, A), with SFV grafts having superior
clinical patency.
Objective follow-up examination with direct intraoper-
ative examination, arteriography, or duplex ultrasonogra-
phy was available on 34 grafts (Table IV; Fig, B). Mean
duration of objective follow-up was 17  4 months. Be-
cause each treatment group contained small numbers of
grafts, the standard error of cumulative primary patency for
SV grafts exceeded 10% by 6 months after surgery (Table
IV; Fig, B). Despite this limitation of the data, the log-rank
test comparing the cumulative primary patency rates be-
tween SV and SFV grafts showed a trend toward statistical
significance (P  .06).
DISCUSSION
Mesenteric ischemia is a rare clinical diagnosis. As such,
reports in the literature rarely contain sufficient patients to
address important questions regarding the optimal tech-
nique for revascularization of the splanchnic circulation.
Consequently, most series of mesenteric reconstructions
include a mixture of both autogenous and prosthetic grafts,
without sufficient numbers of either type of graft material
to reach meaningful conclusions regarding the optimal
conduit for mesenteric bypass. Several series have reported
excellent long-term clinical results with prosthetic graft as
the conduit for such reconstructions.7,9 Occasionally, how-
ever, autogenous conduit is preferable, such as reconstruc-
tions performed in the presence of ischemic or gangrenous
bowel, infected operative fields, or after thrombosis of a
previous mesenteric prosthetic bypass graft. In addition,
some surgeons prefer use of an autogenous conduit be-
cause of its ease of handling or perceived advantage for
patency.
Most surgeons view SV as the autogenous conduit of
choice for arterial bypass grafting, but its use is not without
hazard. In some cases, SV is either absent or inadequate in
caliber or quality for use as an arterial conduit. Some
authors have expressed concern regarding the potential for
kinking of a SV graft, especially when used for a retrograde
bypass to the SMA.16,17 Recent experiences at our institu-
tion with failed mesenteric bypasses performed with SV led
us to investigate the use of SFV as an alternative conduit for
mesenteric arterial bypass.
Schulman, Schulman, and Lledo-Perez18 first reported
the use of SFV as a conduit for femoral-popliteal arterial
bypass, noting acceptable primary patency and clinical out-
comes. Subsequently, our group reported the use of SFV as
a conduit for construction of a neoaortoiliac system for in
situ revascularization of the aorta after excision of infected
aortofemoral prosthetic grafts.11-13 We recently reported
the use of SFV as a conduit for complex brachiocephalic
reconstructions.19 Our experience with SFV has shown
that SFV possesses many of characteristics of an ideal con-
Table III. Life-table of clinical graft patency of vein
grafts
Months
No. of patients
Entering
interval Withdrawn
No. of
graft
stenoses
Cumulative
patency
Standard
error
SV bypass
0 23 7 0 1.00 0.00
6 16 2 2 0.88 0.08
12 12 0 2 0.72 0.12
18 10 1 0 0.72 0.12
24 9 0 0 0.72 0.12
30 9 0 0 0.72 0.12
36 9 0 0 0.72 0.12
42 9 7 2 0.24 0.20
SFV bypass
0 20 5 0 1.00 0.00
6 15 0 0 1.00 0.00
12 15 4 0 1.00 0.00
18 11 2 0 1.00 0.00
24 9 4 0 1.00 0.00
30 5 0 0 1.00 0.00
36 5 0 0 1.00 0.00
42 5 5 0 1.00 0.00
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duit for arterial reconstruction.11,12,19 It is a large-caliber
autogenous conduit that is resistant to infection, kinking,
and thrombosis. This series confirmed that these character-
istics render excellent clinical results for mesenteric arterial
bypass.
This series compared the clinical results of mesenteric
bypasses performed with SV and SFV conduits. In our
experience, three of 11 patients (27%) who received SV
bypass grafts for mesenteric ischemia had recurrent mesen-
teric ischemia develop from SV graft failure in six of 23 SV
grafts. In comparison, none of the patients with SFV bypass
grafts had recurrent symptoms develop. Thus, the clinical
graft patency of SFV grafts proved to be superior to SV
grafts with log-rank test (Table III; Fig, A).
Determination of graft patency with clinical criteria has
its limitations. McMillan et al10 found that only one in
three patients with mesenteric graft failure had recurrent
symptoms in their series. For this reason, we advocate a
program of routine surveillance duplex scanning of all
mesenteric bypasses, regardless of conduit. With this ap-
proach, we obtained objective evidence of graft patency in
34 of 43 mesenteric bypasses in this report (Table IV).
Because each treatment group contained small numbers of
grafts, the standard error of cumulative primary patency
rate for SV grafts exceeded 10% by 6 months after surgery
(Table IV). Despite this limitation of the data, the log-rank
test comparing the objective primary patency between SV
and SFV grafts showed a trend toward statistical signifi-
cance (Fig, B).
On the basis of these data, we believe that SFV is at least
comparable with and probably superior to SV as a conduit
for mesenteric revascularization. Nonetheless, there are
limitations to this study. This series represents a retrospec-
tive review of a heterogeneous patient population in a
single center with experience with this technique. Valida-
tion of this technique in other centers is not yet available.
The long-term durability of SFV as a conduit for mesenteric
arterial reconstructions remains unknown because this se-
ries reports a mean duration of clinical follow-up of 31 6
months and objective follow-up of 17  4 months. Our
initial results appear promising, but further follow-up will
be necessary to confirm the durability of SFV as a conduit in
this arterial bed. An additional shortcoming of this study is
the lack of complete objective follow-up data to document
graft patency. Several patients declined to participate in our
recommended protocol for surveillance duplex scanning or
withdrew from the protocol after an initial normal postop-
erative scan. This decreased the number of grafts at risk and
increased the standard error, so that meaningful compari-
sons could not be obtained from the life-table analysis of
objective graft patency. Finally, this study did not attempt
to compare vein and prosthetic grafts, so any comparisons
between SFV and prosthetic graft would be entirely specu-
lative.
This study was not able to determine conclusively
whether conduit diameter, rather than the type of autoge-
nous conduit per se, is the primary determinant of patency
because preoperative size of SV was not obtained in all
patients. Our subjective impression is that conduit diameter
is an important determinant of patency, so the larger diam-
eter of the SFV, compared with SV, is a distinct advantage.
Table IV. Life-table of objective primary graft patency of
vein grafts
Months
No. of patients
Entering
interval Withdrawn
No. of
graft
stenoses
Cumulative
patency
Standard
error
SV bypass
0 23 12 0 1.00 0.00
6 11 1 2 0.82 0.12
12 8 0 2 0.61 0.15
18 6 1 0 0.61 0.15
24 5 0 0 0.61 0.15
30 5 0 0 0.61 0.15
36 5 0 0 0.61 0.15
42 5 3 2 0.21 0.18
SFV bypass
0 20 10 0 1.00 0.00
6 10 2 0 1.00 0.00
12 8 2 0 1.00 0.00
18 6 4 0 1.00 0.00
24 2 2 0 1.00 0.00
Life-table patency rates for patency rates of SFV and SV grafts. A,
Clinical graft patency of SFV and SV grafts is represented. Solid
lines indicate cumulative patency rates with standard error less than
10%. Patency rates were significantly different with log-rank test
(P .045). B, Objective primary graft patency rates of SFV and SV
grafts are represented. Solid lines indicate cumulative patency rates
with standard error less than 10%. Patency rates were not signifi-
cantly different with log-rank test (P  .06).
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Kinking or a moderate amount of intimal hyperplasia is less
likely to compromise the larger SFV lumen. SV and SFV
conduits of equal diameter would probably have equal
patency, but we rarely encounter SV grafts of comparable
diameter with SFV.
Several potential concerns regarding the use of SFV as a
conduit merit discussion. A potential concern is the addi-
tional operative time necessary to harvest the SFV, espe-
cially in an emergency case. Our experience suggests that
the short segment of SFV necessary for mesenteric bypass
typically requires 20 to 30 minutes of additional operative
time, which we have not found to be prohibitive. The
possibility of aneurysmal dilatation of the SFV has been
discussed.19 We recommend that bypasses with SFV as a
conduit, like all vein grafts, should be surveyed at regular
intervals with duplex ultrasonography. Our practice is to
obtain surveillance duplex scans at 1, 3, 6, and 12 months
after surgery and every 12 months thereafter. With such a
protocol, we noted aneurysmal dilatation of a brachioce-
phalic graft performed with SFV. This case represents only
one graft in more than 200 patients in whom we have used
SFV for arterial reconstruction in a variety of arterial beds.19
Another concern frequently cited as a deterrent to the
use of SFV as a bypass conduit is the potential for venous
morbidity in the donor extremity. We previously reported
that harvesting long segments of SFV resulted in minor
chronic swelling in one third of patients undergoing the
neoaortoiliac system procedure and that the remainder of
patients had no long-term swelling.20 To date, no venous
claudication or ulceration has been observed in patients
after harvesting of the entire SFV for aortofemoral bypass.
Because shorter segments of SFV are necessary for mesen-
teric reconstructions, it is predictable that no significant
venous morbidity has resulted.21 Although we have not
been able to correlate length of vein harvest with the
incidence of chronic limb swelling, it is our impression that
less acute venous morbidity, such as compartment syn-
drome, occurs when shorter segments of SFV are har-
vested.
On the basis of the results of this study, we conclude
that SFV is a safe and effective conduit for mesenteric
arterial reconstructions. Our results suggest that SFV yields
acceptable clinical outcomes for mesenteric arterial bypass,
compared with SV, making SFV a viable alternative when
autogenous conduit is desired for mesenteric arterial recon-
struction.
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